Differentiated
thyroid cancer (DTC) usually has a good prognosis when treated conventionally with
thyroidectomy, radioactive
iodine (RAI) and
thyroid-stimulating hormone suppression, but some
tumors develop a resistance to RAI
therapy, requiring alternative treatments.
Sorafenib,
lenvatinib and
cabozantinib are multikinase inhibitors (MKIs) approved for the treatment of RAI-refractory DTC. The drugs have been shown to improve progression-free survival (PFS) and overall survival (OS) via the inhibition of different
receptor tyrosine kinases (RTKs) that are involved in
tumorigenesis and angiogenesis. Both
sorafenib and
lenvatinib have been approved irrespective of the line of
therapy for the treatment of RAI-refractory DTC, whereas
cabozantinib has only been approved as a second-line treatment. Adverse effects (AEs) such as
hypertension are often seen with MKI treatment, but are generally well manageable. In this review, current clinical studies will be discussed, and the toxicity and safety of
sorafenib,
lenvatinib and
cabozantinib treatment will be evaluated, with a focus on AE
hypertension and its treatment options. In short, treatment-emergent
hypertension (TE-HTN) occurs with all three drugs, but is usually well manageable and leads only to a few dose modifications or even discontinuations. This is emphasized by the fact that
lenvatinib is widely considered the first-line drug of choice, despite its higher rate of TE-HTN.